Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
506results about "Immunoglobulins against fungi/algae/lichens" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Polyclonal antibody composition for treating allergy
InactiveUS6849259B2Efficient removalPotential clinical advantageImmunoglobulins against animals/humansImmunoglobulins against plantsMicrosphereBULK ACTIVE INGREDIENT
A pharmaceutical composition for treating allergy is described. The composition comprises as an active ingredient a recombinant polyclonal antibody or a mixture of different monoclonal antibodies capable of reacting with or binding to an allergen together with one or more pharmaceutically acceptable excipients. The composition may be used topically as a solution, dispersion, powder, or in the form of microspheres. The polyclonal antibody is preferably a recombinant polyclonal antibody produced by phage display technology. The pairing of specific immunoglobulin variable region light chain and heavy chain maintained from the original polyclonal immune response or selected by panning using the allergen in question is preferably maintained by bulk transfer of the pairs into an expression vector.
Owner:SYMPHOGEN AS
Therapeutic using a bispecific antibody
Multivalent, multispecific molecules having at least one specificity for a pathogen and at least one specificity for the HLA class II invariant chain (Ii) are administered to induce clearance of the pathogen. In addition to pathogens, clearance of therapeutic or diagnostic agents, autoantibodies, anti-graft antibodies, and other undesirable compounds may be induced using the multivalent, multispecific molecules.
Owner:IMMUNOMEDICS INC
Method for production of antibodies to specific sites of rapamycin
InactiveUS6709873B1Immunoglobulins against fungi/algae/lichensBiological testingPolyclonal antibodiesDivinyl sulfone
Owner:ISODIAGNOSTIKA
Aflatoxin nano antibody gene pool, construction method and application of aflatoxin nano antibody gene pool as well as aflatoxin B1 nano antibody 2014AFB-G15
ActiveCN103866401AEasy to buildResistant to organic reagentsImmunoglobulins against fungi/algae/lichensBiological testingGene poolAntibody variable region
The invention relates to an aflatoxin nano antibody gene pool, a construction method and application of the aflatoxin nano antibody gene pool as well as an aflatoxin B1 nano antibody 2014AFB-G15. The aflatoxin nano antibody gene pool is prepared by extracting RNA (ribonucleic acid) in alpaca blood after immunization of an aflatoxin B1 antigen, performing specific amplification on a variable region gene of an alpaca heavy chain antibody by adopting an RT-PCR (reverse transcription-polymerase chain reaction) method to obtain an aflatoxin nano antibody VHH gene, and then performing transformation after connecting with a pCANTAB5E (his) vector. The aflatoxin B1 nano antibody 2014AFB-G15 obtained by screening, disclosed by the invention, has the characteristics of organic reagent resistance, high temperature resistance and the like, and is good in stability; the IC50 (half maximal inhibitory concentration) of the aflatoxin B1 nano antibody 2014AFB-G15 to the aflatoxin B1 is 0.66ng / mL, and the cross reactivity of the aflatoxin B1 nano antibody 2014AFB-G15 to the aflatoxins B2, G1,G2 and M1 is 22.6%, 0.95%, 32.1% and 26% respectively.
Owner:INST OF OIL CROPS RES CHINESE ACAD OF AGRI SCI
Endophyte enhanced seedlings with increased pest tolerance
ActiveUS8455395B2Improve toleranceInoculation is highBiocideFungiIncreased toleranceFungal endophyte
The invention provides methods for preparing a conifer seedling with increased tolerance to a pest. A conifer seedling is inoculated with an isolated endophyte when the conifer seedling is susceptible to colonization by the endophyte.
Owner:J D IRVING
Pharmaceutical compositions and methods to vaccinate against candidiasis
InactiveUS20030124134A1Treat prevent alleviateToxic reductionPeptide/protein ingredientsSnake antigen ingredientsHospitalized patientsVirulent characteristics
A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.
Owner:LOS ANGELES BIOMEDICAL RES INST AT UCLA HARBOR MEDICAL CENT +1
Hybridoma cell strain ST03, anti-aflatoxin biosynthesis precursor ST monoclonal antibody and application thereof
ActiveCN103849604ANo cross reactionHigh sensitivityTissue cultureImmunoglobulins against fungi/algae/lichensAbzymeAflatoxin biosynthesis
Owner:OIL CROPS RES INST CHINESE ACAD OF AGRI SCI
Hybridoma cell line 1C11 and anti-aflatoxin general monoclonal antibody generated by same as well as applications thereof
ActiveCN101993855AHigh sensitivityHigh practical application valueMicroorganism based processesTissue cultureCell strainHybridoma cell
The invention provides a hybridoma cell line 1C11 and an anti-aflatoxin general monoclonal antibody secreted by the same as well as the applications thereof. The hybridoma cell line 1C11 can be used for preparing a high-titer aflatoxin antibody, and a mouse hydroperitoneum antibody is measured to reach 5.12*106 by using an ELISA (Enzyme-Linked Immunosorbent Assay). The anti-aflatoxin general monoclonal antibody has high sensitivity, respectively reaches the IC50 (50% inhibiting concentration) of aflatoxin B1, B2, G1 and G2 to be 1.2, 1.3, 2.2 and 18.0 pg / mL, is the antibody with highest sensitivity among currently reported four aflatoxin antibodies, is used for measuring the total aflatoxin amounts, i.e. the total amounts of the aflatoxin B1, B2, G1 and G2 and has great practical application values.
Owner:INST OF OIL CROPS RES CHINESE ACAD OF AGRI SCI
Intrabodies with defined framework that is stable in a reducing environment and applications thereof
InactiveUS7258986B2Stable environmentRaise the possibilityAntibody mimetics/scaffoldsMicroorganismsYeastComplementarity determining region
A method for the isolation of CDRs in a defined framework that is stable and soluble in reducing environment is described as well as thus obtainable scFv. Starting from such scFv with defined framework a scFv library can be generated wherein the framework is conserved while at least one complementary determining region (CDR) is randomized. Such library, e.g. in yeast cells, is suitable for screening for antibody / CDR-interactions or for screening for antibodies.
Owner:ESBATECH
Rapamycin conjugates and antibodies
InactiveUS20060121545A1Organic active ingredientsImmunoglobulins against bacteriaImmunogenicityRapamycin-Binding Proteins
Provided are rapamycin conjugates which are useful as immunogenic molecules for the generation of antibodies specific for rapamycin, for measuring levels of rapamycin or derivatives thereof; for isolating rapamycin binding proteins; and detecting antibodies specific for rapamycin or derivatives thereof. This invention also provides a rapamycin specific monoclonal antibody.
Owner:PFIZER INC
Intrabodies with defined framework that is stable in a reducing environment and applications thereof
InactiveUS7258985B2Stable environmentRaise the possibilityAntibody mimetics/scaffoldsLibrary screeningYeastComplementarity determining region
A method for the isolation of CDRs in a defined framework that is stable and soluble in reducing environment is described as well as thus obtainable scFv. Starting from such scFv with defined framework a scFv library can be generated wherein the framework is conserved while at least one complementary determining region (CDR) is randomized. Such library, e.g. in yeast cells, is suitable for screening for antibody / CDR-interactions or for screening for antibodies.
Owner:ESBATECH
Signal processing devices comprising biological and bio-mimetic components
This invention provides modified phycobilisomes and phycobilisome complexes that are supramolecular complexes with diverse spectral properties, and which may optionally be immobilized on a manufactured solid support. The invention provides a versatile set of highly sensitive signal-generating systems and conjugates that may be used as highly detectable tracers and labels, or in biotransducers comprising phycobilisomes or phycobilisome complexes, and also provides methods for performing specific binding assays using signal-generating systems comprising phycobilisomes as detectable labels. The embodiments of the invention provide the art with an extremely sensitive, nonisotopic detection means for assaying analytes and for sensing molecular events and environmental conditions.
Owner:CUBICCIOTTI ROGER S
Aflatoxin nano-antibody immunosorbent, immunoaffinity column and preparation methods and application of aflatoxin nano-antibody immunosorbent and immunoaffinity column
ActiveCN103861569AImprove stabilityHigh temperature resistantOther chemical processesComponent separationImmunosorbentsGene
Owner:OIL CROPS RES INST CHINESE ACAD OF AGRI SCI
Rapamycin conjugates
InactiveUS7279562B2Organic active ingredientsWithdrawing sample devicesImmunogenicityRapamycin-Binding Proteins
Owner:WYETH LLC
A protein tagging system for in vivo single molecule imaging and control of gene transcription
InactiveUS20170219596A1HydrolasesAntibody mimetics/scaffoldsTranscriptional regulationGenetic element
Methods, compositions, and kits are provided for imaging a polypeptide of interest. Methods, compositions, and kits are also provided for site-specific transcriptional regulation of one or more genetic elements.
Owner:RGT UNIV OF CALIFORNIA
Recombinant antibodies to sclerotinia antigens
InactiveUS20080104734A1Sugar derivativesImmunoglobulins against animals/humansSclerotiniaAnti fungal
The invention is directed to recombinant antibodies which bind to Sclerotinia sclerotiorum antigens and comprise a single chain variable fragment (scFv). The antigen may be selected from SSPG1d or a portion thereof, aspartyl protease or a portion thereof, or whole Sclerotinia sclerotiorum mycelium. The invention also provides an antibody linked to an anti-fungal polypeptide. The invention extends to nucleic acid sequences encoding the antibodies, and expression vectors comprising the nucleic acid sequences. The invention is also directed to transgenic plants, seeds, tissues or cells transformed with the expression vectors. Methods for producing a transgenic plant that is resistant to Sclerotinia sclerotiorum, and for detecting Sclerotinia sclerotiorum in a biological sample utilizing an antibody which binds to Sclerotinia sclerotiorum antigen, and immunoassay kit for same are also provided.
Owner:THE GOVERNORS OF THE UNIV OF ALBERTA
Recombinant antibodies to sclerotinia antigens
The invention is directed to recombinant antibodies which bind to Sclerotinia sclerotiorum antigens and comprise a single chain variable fragment (scFv). The antigen may be selected from SSPG1d or a portion thereof, aspartyl protease or a portion thereof, or whole Sclerotinia sclerotiorum mycelium. The invention also provides an antibody linked to an anti-fungal polypeptide. The invention extends to nucleic acid sequences encoding the antibodies, and expression vectors comprising the nucleic acid sequences. The invention is also directed to transgenic plants, seeds, tissues or cells transformed with the expression vectors. Methods for producing a transgenic plant that is resistant to Sclerotinia sclerotiorum, and for detecting Sclerotinia sclerotiorum in a biological sample utilizing an antibody which binds to Sclerotinia sclerotiorum antigen, and immunoassay kit for same are also provided.
Owner:THE GOVERNORS OF THE UNIV OF ALBERTA
Antibody of fucosylated Golgi protein GP73 and use thereof
InactiveCN101555282AFast detection methodReduce testing costsTissue cultureImmunoglobulins against fungi/algae/lichensCDNA libraryDisease
The invention relates to an antibody against fucosylated protein GP73, a method for preparing the antibody against the fucosylated protein GP73, a reagent for diagnosing liver cancers, a kit for diagnosing the liver cancers, application of the reagent and / or the kit to preparing products for diagnosing liver diseases and a method for preparing purified fucosylated protein GP73. Occurrence, development and metastasis of liver cancers are diagnosed by detecting the fucosylated protein GP73 or the antibody. The antibody against the fucosylated protein GP73 can be more widely used for affinity chromatography, cDNA library screening, immunologic diagnosis or pharmaceutical preparation.
Owner:THE INST OF BASIC MEDICAL SCI OF CHINESE ACAD OF MEDICAL SCI
Polyclonal antibody composition for treating allergy
InactiveUS20050180967A1Good curative effectEfficient removalImmunoglobulins against animals/humansImmunoglobulins against plantsMicrosphereBULK ACTIVE INGREDIENT
Owner:SYMPHOGEN AS
Hapten, immunogens and derivatives of ascomycin useful for preparation of antibodies and immunoassays
The invention teaches derivatives of ascomycin and methods of preparing immunogens and other conjugates useful in immunoassays for quantitatively measuring concentrations of tacrolimus in patient specimens. Antibodies produced from the disclosed immunogens capable of binding to tacrolimus with cross-reactivity of no more than 5% with each of 15-O-demethyl tacrolimus, 31-O-demethyl tacrolimus, and 13,31-O-didemethyl tacrolimus, less than 40% with 13-O-demethyl tacrolimus, and less than 1% with cyclosporin, rapamycin, mycophenolic acid, prednisone, hydrocortisol, and prednisolone are described. Further, immunoassays for measuring the concentration of tacrolimus using such antibodies are taught.
Owner:MICROGENICS CORP
Antibodies, recombinant antibodies, recombinant antibody fragments and fusions mediated plant disease resistance against fungi
InactiveUS20050244901A1Efficient mannerImprove the immunityAntibody mimetics/scaffoldsMicroencapsulation basedPlant tissueFungal microorganisms
A method for the production of fungus resistant transgenic plants, plant cells or plant tissue comprising the introduction of an Ab, rAb, rAb fragment or fusion or vector of the invention or the vectors of the composition of the invention into the genome of a plant, plant cell or plant cell tissue and a transgenic plant cell comprising stably integrated into the genome a polynucleotide or vector of the invention or the vectors of the composition of the invention.
Owner:FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG EV
Method for improving the half-life of soluble viral-specific ligands on mucosal membranes
This invention relates to methods of increasing the half-life of a viral-specific ligand on a mucosal membrane by modifying the viral-specific ligand to bind the bacteria colonized on the mucosal membrane. The invention also provides a chimeric molecule comprising a viral-specific ligand and a bacterial-specific ligand.
Owner:OSEL
Hybridoma cell line 3G1 and anti-alfatoxin B1 monoclonal antibody produced by the same
ActiveCN102747043AHigh sensitivityStrong specificityBiological material analysisTissue cultureAflatoxin BELISA unit
The present invention relates to a hybridoma cell line 3G1 and an anti-alfatoxin B1 monoclonal antibody produced by the hybridoma cell line 3G1. The hybridoma cell line 3G1 (CCTCCNO.C201014) can be used for preparation of a high titer anti-aflatoxin B1 monoclonal antibody, wherein an enzyme-linked immunosorbent assay (ELISA) method is adopted to determine a titer, and the titer is 6.40*10<6>. The anti-aflatoxin B1 monoclonal antibody of the present invention has characteristics of high sensitivity and good specificity, wherein 50% inhibiting concentration on aflatoxin B1 by the monoclonal antibody is 1.6 ng / mL, cross reaction rate with aflatoxin B2 is 6.4%, and cross reaction rates with aflatoxin G1 and G2 are less than 1%. In addition, the anti-aflatoxin B1 monoclonal antibody of the present invention can be used for determination of aflatoxin B1.
Owner:INST OF OIL CROPS RES CHINESE ACAD OF AGRI SCI
Gene disruption methodologies for drug target discovery
The present invention provides methods and compositions that enable the experimental determination as to whether any gene in the genome of a diploid pathogenic organism is essential, and whether it is required for virulence or pathogenicity. The methods involve the construction of genetic mutants in which one allele of a specific gene is inactivated while the other allele of the gene is placed under conditional expression. The identification of essential genes and those genes critical to the development of virulent infections, provides a basis for the development of screens for new drugs against such pathogenic organisms. The present invention further provides Candida albicans genes that are demonstrated to be essential and are potential targets for drug screening. The nucleotide sequence of the target genes can be used for various drug discovery purposes, such as expression of the recombinant protein, hybridization assay and construction of nucleic acid arrays. The uses of proteins encoded by the essential genes, and genetically engineered cells comprising modified alleles of essential genes in various screening methods are also encompassed by the invention.
Owner:MERCK & CO INC
Method of inhibiting Candida-related infections using donor selected or donor stimulated immunoglobulin compositions
InactiveUS20050287146A1Inhibit growthInhibit severityImmunoglobulins against bacteriaBiological material analysisYeastStaphylococcus
A method for treating or preventing infections from yeast of the Candida species is provided wherein an immunoglobulin composition containing high titers of antibodies to staphylococcal adhesins ClfA and SdrG is administered in an amount effective to inhibit the growth and progression of Candidial infections. The compositions and methods of the present invention are advantageous in that they can be used to treat both staphylococcal and Candidial infections at the same time, and they are particularly effective in treating or preventing late-onset sepsis in neonates.
Owner:TEXAS A&M UNIVERSITY +1
Enzyme-linked immunosorbent assay kit for detecting aflatoxin B1-containing medicine and application for same
The invention provides an enzyme-linked immunosorbent assay kit for detecting an aflatoxin B1-containing medicine and an application for the same. The enzyme-linked immunosorbent assay (ELISA) kit comprises an ELISA plate coated with a coating antigen, an enzyme label, aflatoxin B1 specific antibody working solution (contained in the case that the coating antigen on the ELISA plate and the enzyme label are enzyme-labelled antibodies or enzyme-labelled antigens), aflatoxin B1 standard substance solution, substrate developing solution, stopping solution, concentrated washing solution and concentrated compound solution. The method for detecting aflatoxin B1 by virtue of the kit provided by the invention comprises the following steps of: performing sample pre-treatment at first, and then detecting by virtue of the kit, and finally analysing the detected result. The enzyme-linked immunosorbent assay kit provided by the invention can be used for detecting the residual amount of aflatoxin B1 in samples such as oil, peanuts and grains, as well as is simple and convenient to operate, low in expense, high in sensitivity, capable of being monitored in the field, and suitable for screening lots of samples.
Owner:BEIJING KWINBON BIOTECH
Hybridoma cell strain 2D3, monoclonal antibody to zearalenone secreted by same and application of monoclonal antibody
The invention provides a hybridoma cell strain 2D3, a monoclonal antibody to zearalenone secreted by the hybridoma cell strain 2D3 and application of the monoclonal antibody. The hybridoma cell strain 2D3 is preserved in China Center for Type Culture Collection with an accession number of CCTCC No. C201328 and can be used for preparation of a high-titer monoclonal antibody to zearalenone. According to detection results of enzyme linked immunosorbent assay (ELISA), the titer of the monoclonal antibody to zearalenone prepared through purification of mouse ascites can reach 1.5 * 10<5>. The monoclonal antibody to zearalenone has high sensitivity, half maximal inhibitory concentration IC50 of 20 pg / mL to zearalenone and cross reactivity of 4.9%, 3.3% and 3.2% with beta-zearalanel, alpha-zearalanel and beta-zeranol, respectively. The monoclonal antibody to zearalenone can be used for determination of the content of zearalenone.
Owner:INST OF OIL CROPS RES CHINESE ACAD OF AGRI SCI
Screening and application of single-chain antibody against fumonisin
InactiveCN102453093AHigh affinityReduce manufacturing costImmunoglobulins against fungi/algae/lichensBiological testingEscherichia coliSingle-Chain Antibodies
The invention belongs to the technical field of genetic engineering, and in particular relates to screening of a single-chain antibody against fumonisin and application thereof in immunoassay of fumonisin. The screening method comprises the following steps of: directly setting off from coupled antigen FB1-KLH(keyhole limpet hemocyanin) immunized mouse spleen cells, establishing a single-chain antibody gene library by a molecular cloning method and technology, then screening by a phage display technology, expressing ELISA(enzyme-linked immuno sorbent assay) test, sequencing, and finally obtaining the single-chain antibody against fumonisin named as FB-Mu 1H3 with high affinity and a coding gene thereof. The single-chain antibody can be directly applied to assay of fumonisin after being expressed and purified in a large quantity in escherichia coli, and the applications include assay of fumonisin pollution in field crops, feed, grain or food.
Owner:HUAZHONG AGRI UNIV
Hybridoma cell strain 4F4 and antibody thereof
ActiveCN106591240AHigh antibody titerStrong specificityTissue cultureImmunoglobulins against fungi/algae/lichensTenuazonic acidAlternaria helianthi
The invention relates to a hybridoma cell strain 4F4 and an antibody thereof. The hybridoma cell strain 4F4 is preserved in China Center for Type Culture Collection on Dec. 27, 2016 with the preservation number of CCTCC NO:C201702. The hybridoma cell strain 4F4 generates an anti-tenuazonic acid monoclonal antibody, specifically detects tenuazonic acid, and is of great significance to detect the tenuazonic acid.
Owner:SOUTHWEST UNIVERSITY
New bispecific format suitable for use in high-through-put screening
ActiveUS20170081404A1Not susceptible to inappropriate dimerizationEasy to assembleAntibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsHigh-Throughput Screening MethodsCoupling
The present disclosure relates to a novel bispecific protein complex and a method of using the complexes to screen for synergistic or novel biological function. The bispecific format is particularly suitable for high-throughput screening because all of its components can be expressed from cells as individual units and the units can be assembled simply by mixing without employing conjugation or coupling chemistry.
Owner:UCB PHARMA SRL
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com